3 ms·
Yes. But they also charge more because they can. Healthcare is not special. It's like any other limited resources. That is, increase demand and the price goes u
by chiefalchemist 9y ago
Yes. But they also charge more because they can. Healthcare is not special. It's like any other limited resources. That is, increase demand and the price goes up.
On the other hand, lower demand and prices will fall.
As it is we're getting older and intentionally living a more unhealthy lifestyle, but expecting prices to fall?
No doubt there are vast disfunction in the current system. However, the biggest - literally - component of that system are the humam seeking / needing care. What's more unhealthy, those people or the insurance companies? I can't see the line between the diabetes dot or the smoking dot and the insurance companies.
- ZenoArrow 9y ago> "Yes. But they also charge more because they can. Healthcare is not special. It's like any other limited resources. That is, increase demand and the price goes up." If you're talking about pharmaceutical prices, there are ways around that. For example, drugs that are FDA approved and available elsewhere in the world for a lower price should be able to be legally imported and sold at that lower price. To give an example of how this could be implemented, there was a bill that was proposed to allow drugs from Canada to be imported and sold: https://www.pharmamanufacturing.com/articles/2017/senators-propose-bill-for-canadian-drug-import/ https://www.pharmamanufacturing.com/articles/2017/senators-p... This bill was for the same drugs that legally available in the US, but sold at a cheaper price in Canada. https://twitter.com/sensanders/status/819404681806016513?lang=en https://twitter.com/sensanders/status/819404681806016513?lan... By increasing competition from imports, drug prices can come down. Also, allowing generics to come to market faster for the most commonly used drugs (i.e. cutting down the time for which a single pharmaceutical company has a monopoly on producing a drug) is another approach that can stop pharmaceutical companies from over-inflating drug prices in the US.